November 16, 2021
Aiforia achieves CE-IVD mark for clinical PD-L1 AI model in lung cancer diagnostics
Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 million deaths occurring¹. Fortunately immunotherapies are increasing in prominence and efficacy². A popular target for these novel therapeutics is PD-L1, a vital biomarker indicating cancer progression³. The calculation of PD-L1 presence in tumors is routinely used in clinical pathology as a ...
Written by Aiforia